LGL Partners’s MacroGenics MGNX Stock Holding History

LGL Partners’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$52K	–	128
2022 Q3	$52K	Buy	+15,000	New	+$57.4K	0.01%	151

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

LGL Partners's MGNX Position: Q4 2022 in Review

LGL Partners sold out of MacroGenics (MGNX) in Q4 2022, closing a stake of 15,000 shares — an estimated $52K sold.

LGL Partners first reported a position in MGNX in Q3 2022 and held it in 1 quarter. The position peaked at $52K in Q3 2022. 135 funds tracked by Wall St. Rank hold MGNX as of Q4 2022.

LGL Partners reported no remaining MacroGenics position as of Q4 2022 after selling out during the quarter.
LGL Partners sold 15,000 MacroGenics shares in Q4 2022, an estimated $52K.
LGL Partners first reported a position in MacroGenics in Q3 2022 and held it in 1 quarter.
LGL Partners's MacroGenics position peaked at $52K in Q3 2022.
135 funds tracked by Wall St. Rank held MacroGenics as of Q4 2022.

Based on LGL Partners's 13F filing for Q4 2022, filed 14 Feb 2023.